

In the Claims:

Please amend the claims as follows:

1. (Original) A method of treating multi-organ failure, kidney dysfunction, or wound healing, said method comprising delivering a therapeutic amount of stem cells to a patient in need thereof.
2. (Original) The method of claim 1 wherein said stem cells comprise hematopoietic stem cells.
3. (Original) The method of claim 1 wherein said stem cells comprise mesenchymal stem cells.
4. (Original) The method of claim 1 wherein said stem cells comprise hemangioblasts.
5. (Original) The method of claim 1 wherein said stem cells comprise non-hematopoietic stem cells.
6. (Original) The method of claim 1 wherein said stem cells comprise non-transformed stem cells.
7. (Original) The method of claim 1 wherein said stem cells comprise genetically modified stem cells, wherein protective potency of said cells is augmented by genetic modification prior to administration in a patient in need thereof.
8. (Original) ~~The method of claim 1 wherein said stem cells comprise autologous cells.~~
9. (Original) The method of claim 1 wherein said stem cells comprise allogeneic cells.

10. (Original) The method of claim 1 wherein said kidney dysfunction comprises acute renal failure, early dysfunction of kidney transplant, or chronic renal failure.

11. (Original) The method of claim 1 wherein said cells are pre-differentiated into renal tubular cells, vascular endothelial cells or other kidney-or other organ specific cells.

12. (Original) The method of claim 4 wherein said hemangioblasts are pre-differentiated into endothelial cells.

13. (Original) The method of claim 2 wherein hematopoietic stem cells are pre-differentiated in vitro.

14. (Original) The method of claim 13 wherein said hematopoietic stem cells are pre-differentiated into endothelial cells.

15. (Original) The method of claim 3 wherein mesenchymal stem cells are pre-differentiated in vitro.

16. (Original) The method of claim 15 wherein said mesenchymal stem cells are pre-differentiated into endothelial cells.

17. (Original) The method of claim 15 wherein said mesenchymal stem cells are pre-differentiated into renal tubular cells.

18. (Original) A method of treating multi-organ failure, kidney dysfunction, wound healing or organ dysfunction comprising delivering a therapeutic amount of a stimulant of stem cell mobilization to a patient in need thereof;

wherein the stimulant mobilizes stem cells to the organs in need thereof.

19. (Original) The method of claim 18 wherein said stem cells comprise endothelial cells.

20. (Original) The method of claim 18 wherein said stem cells comprise endothelial precursor cells.

21. (Original) A method of treating organ dysfunction, said method comprising delivering a therapeutic amount of pre-differentiated stem cells to a patient in need thereof; wherein said cells are pre-differentiated in vitro into organ specific cells.

22. (Original) A method of treating organ dysfunction, said method comprising delivering a therapeutic amount of hemangioblasts to a patient in need thereof.

23-44. (Cancelled)

45. (Original) A method of treating multi-organ failure, kidney dysfunction, organ dysfunction, or wound healing, said method comprising delivering a therapeutic amount of a mixture hematopoietic stem cells and mesenchymal stem cells to a patient in need thereof.

46. (Original) The method of claim 45 wherein said kidney dysfunction comprises acute renal failure, early dysfunction of kidney transplant, or chronic renal failure.

47. (Original) The method of claim 45 wherein said hematopoietic stem cells and said mesenchymal stem cells comprise autologous cells.

48. (Original) The method of claim 45 wherein said hematopoietic stem cells and said mesenchymal stem cells comprise allogeneic cells.

49. (Original) The method of claim 45 wherein a ratio of said hematopoietic stem cells to said mesenchymal stem cells is optimized for the treatment of kidney dysfunction or other organ dysfunction.

50. (Original) The method of claim 49 wherein said stem cells are delivered to said patient in a ratio of about 0.1:1 to about 50:1 hematopoietic stem cells to mesenchymal stem cells.

51. (Original) A composition for the treatment of multi-organ failure, organ dysfunction, or wound healing, said composition comprising a therapeutic amount of hematopoietic stem cells and mesenchymal stem cells.

52. (Original) The composition of claim 51 wherein said kidney dysfunction comprises acute renal failure, early dysfunction of kidney transplant, or chronic renal failure.

53. (Original) The composition of 51 wherein a ratio of said hematopoietic stem cells to said mesenchymal stem cells is optimized for the treatment of kidney dysfunction or other organ dysfunction.

54-59. (Cancelled)